Arcus Biosciences, Inc. - Common Stock (RCUS)

Historical Holders from Q1 2018 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
RCUS on NYSE
Shares outstanding
122,470,452
Price per share
$23.83
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
100,610,225
Total reported value
$1,368,169,061
% of total 13F portfolios
0%
Share change
+550,683
Value change
+$17,186,653
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
185
Price from insider filings
$23.20
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Arcus Biosciences, Inc. - Common Stock (RCUS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GILEAD SCIENCES, INC. 26% -14% $427,376,736 31,424,760 0% GILEAD SCIENCES, INC. 03 Nov 2025
BlackRock, Inc. 10% +11% $303,514,602 +$65,766,227 12,736,927 +28% BlackRock, Inc. 31 Dec 2025
Point72 Asset Management, L.P. 4.1% -28% $58,921,714 -$20,381,232 4,332,479 -26% Point72 Asset Management, L.P. 30 Sep 2025
As of 30 Sep 2025, Arcus Biosciences, Inc. - Common Stock (RCUS) has 185 institutional shareholders filing 13F forms. They hold 100,610,225 shares. of 122,470,452 outstanding shares (82%) .

Top 25 institutional shareholders own 72% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
GILEAD SCIENCES, INC. 26% 31,424,760 0% 24% $427,376,736
BlackRock, Inc. 9.6% 11,810,866 +3.1% 0% $160,627,778
VANGUARD GROUP INC 5.4% 6,629,453 +1.1% 0% $90,160,561
Point72 Asset Management, L.P. 3.5% 4,332,479 -27% 0.13% $58,921,714
Woodline Partners LP 3.1% 3,769,684 -5.8% 0.24% $51,267,702
SUVRETTA CAPITAL MANAGEMENT, LLC 3% 3,688,858 0% 1.5% $50,168,469
STATE STREET CORP 2.8% 3,394,854 -6.5% 0% $46,170,014
Siren, L.L.C. 2.4% 2,912,077 +81% 1.5% $39,604,247
FMR LLC 1.9% 2,296,021 -11% 0% $31,225,884
GEODE CAPITAL MANAGEMENT, LLC 1.3% 1,598,409 +0.13% 0% $21,740,690
MORGAN STANLEY 1.3% 1,536,088 +4.5% 0% $20,890,796
DIMENSIONAL FUND ADVISORS LP 1.2% 1,502,463 -9.5% 0% $20,431,602
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.2% 1,419,985 +1.7% 0.05% $19,312,000
BANK OF AMERICA CORP /DE/ 1.1% 1,360,781 +173% 0% $18,506,622
WELLINGTON MANAGEMENT GROUP LLP 1% 1,266,289 +35% 0% $17,221,530
Sofinnova Investments, Inc. 1% 1,222,263 +0.51% 1% $16,622,777
RA CAPITAL MANAGEMENT, L.P. 0.93% 1,136,364 0% 0.19% $15,454,550
JACOBS LEVY EQUITY MANAGEMENT, INC 0.91% 1,120,062 +39% 0.06% $15,232,843
GOLDMAN SACHS GROUP INC 0.78% 950,589 +47% 0% $12,928,010
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.71% 871,150 +12% 0% $11,847,640
Fisher Asset Management, LLC 0.6% 729,153 +727% 0% $9,916,480
NORTHERN TRUST CORP 0.58% 707,796 +2.4% 0% $9,626,027
Parkman Healthcare Partners LLC 0.53% 652,680 +8.9% 0.97% $8,876,448
MILLENNIUM MANAGEMENT LLC 0.52% 634,944 -19% 0.01% $8,635,238
DAFNA Capital Management LLC 0.51% 627,626 0% 2.1% $8,535,714

Institutional Holders of Arcus Biosciences, Inc. - Common Stock (RCUS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 49,345 $1,175,912 -$4,017,907 2,382.98% 4
2025 Q3 100,610,225 $1,368,169,061 +$17,186,653 1,360% 185
2025 Q2 99,755,332 $811,781,525 +$23,005,564 814% 182
2025 Q1 97,195,653 $762,981,034 +$76,941,562 785% 183
2024 Q4 83,908,948 $1,249,338,530 -$20,066,563 1,489% 185
2024 Q3 53,247,799 $814,284,251 +$20,378,066 1,529% 184
2024 Q2 51,959,262 $791,347,395 -$14,443,594 1,523% 192
2024 Q1 52,748,847 $995,767,728 -$4,089,388 1,888% 170
2023 Q4 38,621 $737,661 +$138,322 1,910% 2
2023 Q3 52,731,288 $946,513,881 -$31,073,101 1,795% 183
2023 Q2 54,622,822 $1,108,501,818 -$12,806,653 2,031% 176
2023 Q1 55,488,001 $1,012,085,300 +$18,038,794 1,824% 176
2022 Q4 53,760,173 $1,111,721,654 +$35,391,294 2,068% 196
2022 Q3 51,986,718 $1,360,031,715 -$627,951 2,615.98% 167
2022 Q2 52,406,459 $1,328,118,467 +$7,694,623 2,534% 158
2022 Q1 49,818,401 $1,573,294,880 -$27,760,261 3,156% 142
2021 Q4 50,819,461 $2,056,304,533 +$106,243,948 4,046.99% 134
2021 Q3 48,272,046 $1,683,510,642 +$59,850,899 3,487.01% 128
2021 Q2 45,147,217 $1,239,732,813 +$11,634,013 2,746.01% 127
2021 Q1 44,736,428 $1,254,920,338 +$5,081,778 2,808% 144
2020 Q4 44,131,082 $1,145,645,273 +$12,233,310 2,596% 140
2020 Q3 43,812,542 $751,074,949 +$13,227,367 1,714.01% 125
2020 Q2 41,839,088 $1,034,189,021 +$375,000,468 2,474% 137
2020 Q1 26,986,338 $374,565,368 +$109,359 1,387.99% 89
2019 Q4 27,101,574 $273,724,351 -$3,032,498 1,010.01% 74
2019 Q3 25,783,897 $234,660,496 -$570,018 910% 71
2019 Q2 26,404,077 $209,754,107 +$6,130,574 795% 74
2019 Q1 25,775,327 $321,931,437 -$12,805,993 1,249.01% 61
2018 Q4 26,851,367 $289,187,060 -$5,146,111 1,077% 62
2018 Q3 22,435,039 $312,743,356 +$919,625 1,394% 54
2018 Q2 22,392,242 $274,083,081 +$32,064,856 1,224% 60
2018 Q1 16,255,471 $250,516,107 +$250,516,526 1,544% 55